ID   ACHA9_RAT               Reviewed;         479 AA.
AC   P43144; Q6PW49;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   21-JUN-2005, sequence version 2.
DT   02-OCT-2024, entry version 182.
DE   RecName: Full=Neuronal acetylcholine receptor subunit alpha-9;
DE   AltName: Full=Nicotinic acetylcholine receptor subunit alpha-9;
DE            Short=NACHR alpha-9;
DE   Flags: Precursor;
GN   Name=Chrna9; Synonyms=Acra9;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Olfactory epithelium;
RX   PubMed=7954834; DOI=10.1016/0092-8674(94)90555-x;
RA   Elgoyhen A.B., Johnson D.S., Boulter J., Vetter D.E., Heinemann S.F.;
RT   "Alpha 9: an acetylcholine receptor with novel pharmacological properties
RT   expressed in rat cochlear hair cells.";
RL   Cell 79:705-715(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RA   Groot-Kormelink P.J.;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=10713500; DOI=10.1016/s0378-5955(99)00214-2;
RA   Katz E., Verbitsky M., Rothlin C.V., Vetter D.E., Heinemann S.F.,
RA   Elgoyhen A.B.;
RT   "High calcium permeability and calcium block of the alpha9 nicotinic
RT   acetylcholine receptor.";
RL   Hear. Res. 141:117-128(2000).
RN   [4]
RP   FUNCTION.
RX   PubMed=11044723; DOI=10.1016/s0028-3908(00)00124-6;
RA   Verbitsky M., Rothlin C.V., Katz E., Elgoyhen A.B.;
RT   "Mixed nicotinic-muscarinic properties of the alpha9 nicotinic cholinergic
RT   receptor.";
RL   Neuropharmacology 39:2515-2524(2000).
RN   [5]
RP   INTERACTION WITH CHRNA10, SUBUNIT, TISSUE SPECIFICITY, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=11248107; DOI=10.1073/pnas.051622798;
RA   Elgoyhen A.B., Vetter D.E., Katz E., Rothlin C.V., Heinemann S.F.,
RA   Boulter J.;
RT   "Alpha10: a determinant of nicotinic cholinergic receptor function in
RT   mammalian vestibular and cochlear mechanosensory hair cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:3501-3506(2001).
RN   [6]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CHRNA10.
RX   PubMed=12117536; DOI=10.1016/s0378-5955(02)00380-5;
RA   Weisstaub N., Vetter D.E., Elgoyhen A.B., Katz E.;
RT   "The alpha9alpha10 nicotinic acetylcholine receptor is permeable to and is
RT   modulated by divalent cations.";
RL   Hear. Res. 167:122-135(2002).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=12401316; DOI=10.1016/s0306-4522(02)00274-9;
RA   Lips K.S., Pfeil U., Kummer W.;
RT   "Coexpression of alpha 9 and alpha 10 nicotinic acetylcholine receptors in
RT   rat dorsal root ganglion neurons.";
RL   Neuroscience 115:1-5(2002).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH CHRNA10.
RX   PubMed=14742688; DOI=10.1124/mol.65.2.453;
RA   Baker E.R., Zwart R., Sher E., Millar N.S.;
RT   "Pharmacological properties of alpha 9 alpha 10 nicotinic acetylcholine
RT   receptors revealed by heterologous expression of subunit chimeras.";
RL   Mol. Pharmacol. 65:453-460(2004).
RN   [9]
RP   SITE THR-86, AND MUTAGENESIS OF SER-36; SER-44; ALA-54; THR-86; ARG-101;
RP   SER-147 AND SER-166.
RX   PubMed=22774872; DOI=10.1111/j.1471-4159.2012.07867.x;
RA   Azam L., McIntosh J.M.;
RT   "Molecular basis for the differential sensitivity of rat and human
RT   alpha9alpha10 nAChRs to alpha-conotoxin RgIA.";
RL   J. Neurochem. 122:1137-1144(2012).
RN   [10]
RP   MUTAGENESIS OF TRP-176.
RX   PubMed=18295795; DOI=10.1016/j.jmb.2008.01.082;
RA   Ellison M., Feng Z.P., Park A.J., Zhang X., Olivera B.M., McIntosh J.M.,
RA   Norton R.S.;
RT   "Alpha-RgIA, a novel conotoxin that blocks the alpha9alpha10 nAChR:
RT   structure and identification of key receptor-binding residues.";
RL   J. Mol. Biol. 377:1216-1227(2008).
RN   [11]
RP   SITE ASP-146, MUTAGENESIS OF THR-86 AND ASP-146, AND SUBUNIT.
RX   PubMed=25740413; DOI=10.1124/mol.114.096511;
RA   Azam L., Papakyriakou A., Zouridakis M., Giastas P., Tzartos S.J.,
RA   McIntosh J.M.;
RT   "Molecular interaction of alpha-conotoxin RgIA with the rat alpha9alpha10
RT   nicotinic acetylcholine receptor.";
RL   Mol. Pharmacol. 87:855-864(2015).
RN   [12]
RP   ERRATUM OF PUBMED:25740413.
RX   PubMed=27559150; DOI=10.1124/mol.114.096511err;
RA   Azam L., Papakyriakou A., Zouridakis M., Giastas P., Tzartos S.J.,
RA   McIntosh J.M.;
RT   "Corrections to 'Molecular interaction of alpha-conotoxin RgIA with the rat
RT   alpha9alpha10 nicotinic acetylcholine receptor'.";
RL   Mol. Pharmacol. 90:415-417(2016).
CC   -!- FUNCTION: Ionotropic receptor with a probable role in the modulation of
CC       auditory stimuli. Agonist binding induces a conformation change that
CC       leads to the opening of an ion-conducting channel across the plasma
CC       membrane. The channel is permeable to a range of divalent cations
CC       including calcium, the influx of which may activate a potassium current
CC       which hyperpolarizes the cell membrane. In the ear, this leads to a
CC       reduction in basilar membrane motion, altering the activity of auditory
CC       nerve fibers and reducing the range of dynamic hearing. This may
CC       protect against acoustic trauma. May also regulate keratinocyte
CC       adhesion. {ECO:0000269|PubMed:10713500, ECO:0000269|PubMed:11044723,
CC       ECO:0000269|PubMed:11248107, ECO:0000269|PubMed:12117536,
CC       ECO:0000269|PubMed:14742688, ECO:0000269|PubMed:7954834, ECO:0000305}.
CC   -!- SUBUNIT: Can form homo- or heterooligomeric channels in conjunction
CC       with CHRNA10. The native outer hair cell receptor may be composed of
CC       CHRNA9-CHRNA10 heterooligomers. Interacts with the alpha-conotoxin RgIA
CC       (PubMed:25740413). {ECO:0000269|PubMed:11248107,
CC       ECO:0000269|PubMed:12117536, ECO:0000269|PubMed:14742688,
CC       ECO:0000269|PubMed:25740413, ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Postsynaptic cell membrane {ECO:0000305}; Multi-
CC       pass membrane protein {ECO:0000305}. Cell membrane
CC       {ECO:0000269|PubMed:10713500, ECO:0000269|PubMed:11248107,
CC       ECO:0000269|PubMed:12117536, ECO:0000269|PubMed:7954834}; Multi-pass
CC       membrane protein {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Detected in the nasal epithelium, in the outer hair
CC       cells of the cochlea, in the pars tuberalis of the hypophysis, and in
CC       the developing muscle of the tongue. Also expressed in the neurons of
CC       dorsal root ganglia. {ECO:0000269|PubMed:11248107,
CC       ECO:0000269|PubMed:12401316, ECO:0000269|PubMed:7954834}.
CC   -!- MISCELLANEOUS: The heterooligomeric receptor composed of CHRNA9 and
CC       CHRNA10 has an atypical pharmacological profile, binding several non-
CC       nicotinic ligands including strychnine (a glycine receptor antagonist)
CC       and atropine (a muscarinic acetylcholine receptor antagonist).
CC       {ECO:0000269|PubMed:7954834}.
CC   -!- SIMILARITY: Belongs to the ligand-gated ion channel (TC 1.A.9) family.
CC       Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha-9/CHRNA9 sub-
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U12336; AAA56720.1; -; mRNA.
DR   EMBL; AY574257; AAS90353.1; -; mRNA.
DR   PIR; A55382; A55382.
DR   RefSeq; NP_075219.1; NM_022930.1.
DR   AlphaFoldDB; P43144; -.
DR   SMR; P43144; -.
DR   ComplexPortal; CPX-224; Neuronal nicotinic acetylcholine receptor complex, alpha9-alpha10.
DR   ComplexPortal; CPX-228; Neuronal nicotinic acetylcholine receptor complex, alpha9.
DR   STRING; 10116.ENSRNOP00000003382; -.
DR   BindingDB; P43144; -.
DR   ChEMBL; CHEMBL2585; -.
DR   DrugCentral; P43144; -.
DR   GuidetoPHARMACOLOGY; 469; -.
DR   GlyCosmos; P43144; 2 sites, No reported glycans.
DR   GlyGen; P43144; 2 sites.
DR   PhosphoSitePlus; P43144; -.
DR   PaxDb; 10116-ENSRNOP00000003382; -.
DR   DNASU; 65024; -.
DR   GeneID; 65024; -.
DR   KEGG; rno:65024; -.
DR   UCSC; RGD:621534; rat.
DR   AGR; RGD:621534; -.
DR   CTD; 55584; -.
DR   RGD; 621534; Chrna9.
DR   VEuPathDB; HostDB:ENSRNOG00000002484; -.
DR   eggNOG; KOG3645; Eukaryota.
DR   HOGENOM; CLU_018074_0_0_1; -.
DR   InParanoid; P43144; -.
DR   OrthoDB; 5489962at2759; -.
DR   PhylomeDB; P43144; -.
DR   TreeFam; TF315605; -.
DR   Reactome; R-RNO-629594; Highly calcium permeable postsynaptic nicotinic acetylcholine receptors.
DR   PRO; PR:P43144; -.
DR   Proteomes; UP000002494; Chromosome 14.
DR   Bgee; ENSRNOG00000002484; Expressed in ovary.
DR   GO; GO:0005892; C:acetylcholine-gated channel complex; IDA:RGD.
DR   GO; GO:0098981; C:cholinergic synapse; IDA:SynGO.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0099634; C:postsynaptic specialization membrane; IDA:SynGO.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:1902495; C:transmembrane transporter complex; IBA:GO_Central.
DR   GO; GO:0022848; F:acetylcholine-gated monoatomic cation-selective channel activity; IDA:RGD.
DR   GO; GO:0005262; F:calcium channel activity; IEA:UniProtKB-KW.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IEA:InterPro.
DR   GO; GO:1904315; F:transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential; IDA:SynGO.
DR   GO; GO:0007268; P:chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0099565; P:chemical synaptic transmission, postsynaptic; ISO:RGD.
DR   GO; GO:0050910; P:detection of mechanical stimulus involved in sensory perception of sound; ISO:RGD.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; ISO:RGD.
DR   GO; GO:0042472; P:inner ear morphogenesis; ISO:RGD.
DR   GO; GO:0051899; P:membrane depolarization; ISO:RGD.
DR   GO; GO:0098655; P:monoatomic cation transmembrane transport; ISO:RGD.
DR   GO; GO:0006812; P:monoatomic cation transport; ISO:RGD.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IMP:RGD.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISO:RGD.
DR   GO; GO:0010996; P:response to auditory stimulus; ISO:RGD.
DR   CDD; cd19022; LGIC_ECD_nAChR_A9; 1.
DR   CDD; cd19051; LGIC_TM_cation; 1.
DR   Gene3D; 2.70.170.10; Neurotransmitter-gated ion-channel ligand-binding domain; 1.
DR   Gene3D; 1.20.58.390; Neurotransmitter-gated ion-channel transmembrane domain; 2.
DR   InterPro; IPR006202; Neur_chan_lig-bd.
DR   InterPro; IPR036734; Neur_chan_lig-bd_sf.
DR   InterPro; IPR006201; Neur_channel.
DR   InterPro; IPR036719; Neuro-gated_channel_TM_sf.
DR   InterPro; IPR038050; Neuro_actylchol_rec.
DR   InterPro; IPR006029; Neurotrans-gated_channel_TM.
DR   InterPro; IPR018000; Neurotransmitter_ion_chnl_CS.
DR   InterPro; IPR002394; Nicotinic_acetylcholine_rcpt.
DR   NCBIfam; TIGR00860; LIC; 1.
DR   PANTHER; PTHR18945:SF489; NEURONAL ACETYLCHOLINE RECEPTOR SUBUNIT ALPHA-9; 1.
DR   PANTHER; PTHR18945; NEUROTRANSMITTER GATED ION CHANNEL; 1.
DR   Pfam; PF02931; Neur_chan_LBD; 1.
DR   Pfam; PF02932; Neur_chan_memb; 1.
DR   PRINTS; PR00254; NICOTINICR.
DR   PRINTS; PR00252; NRIONCHANNEL.
DR   SUPFAM; SSF90112; Neurotransmitter-gated ion-channel transmembrane pore; 1.
DR   SUPFAM; SSF63712; Nicotinic receptor ligand binding domain-like; 1.
DR   PROSITE; PS00236; NEUROTR_ION_CHANNEL; 1.
PE   1: Evidence at protein level;
KW   Calcium; Calcium channel; Calcium transport; Cell membrane; Disulfide bond;
KW   Glycoprotein; Ion channel; Ion transport; Ligand-gated ion channel;
KW   Membrane; Postsynaptic cell membrane; Receptor; Reference proteome; Signal;
KW   Synapse; Transmembrane; Transmembrane helix; Transport.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..479
FT                   /note="Neuronal acetylcholine receptor subunit alpha-9"
FT                   /id="PRO_0000000372"
FT   TOPO_DOM        26..237
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        238..262
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        269..287
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        302..323
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        324..457
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        458..476
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   SITE            86
FT                   /note="Key residue important for potent inhibition of the
FT                   CHRNA9-CHRNA10 receptor by the alpha-conotoxin RgIA (AC
FT                   P0C1D0)"
FT                   /evidence="ECO:0000269|PubMed:22774872"
FT   SITE            146
FT                   /note="Key residue important for potent inhibition of the
FT                   CHRNA9-CHRNA10 receptor by the alpha-conotoxin RgIA (AC
FT                   P0C1D0)"
FT                   /evidence="ECO:0000269|PubMed:25740413"
FT   CARBOHYD        57
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        170
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        155..169
FT                   /evidence="ECO:0000250|UniProtKB:Q9UGM1"
FT   DISULFID        219..220
FT                   /evidence="ECO:0000250|UniProtKB:Q9UGM1"
FT   MUTAGEN         36
FT                   /note="S->N: No significant change in potency of inhibition
FT                   of the CHRNA9-CHRNA10 receptor by the alpha-conotoxin
FT                   RgIA."
FT                   /evidence="ECO:0000269|PubMed:22774872"
FT   MUTAGEN         44
FT                   /note="S->N: No significant change in potency of inhibition
FT                   of the CHRNA9-CHRNA10 receptorby the alpha-conotoxin RgIA."
FT                   /evidence="ECO:0000269|PubMed:22774872"
FT   MUTAGEN         54
FT                   /note="A->K: No significant change in potency of inhibition
FT                   of the CHRNA9-CHRNA10 receptorby the alpha-conotoxin RgIA."
FT                   /evidence="ECO:0000269|PubMed:22774872"
FT   MUTAGEN         86
FT                   /note="T->E: The CHRNA9-CHRNA10 receptor is 20-fold less
FT                   potently inhibited by the alpha-conotoxin RgIA."
FT                   /evidence="ECO:0000269|PubMed:25740413"
FT   MUTAGEN         86
FT                   /note="T->I: The CHRNA9-CHRNA10 receptor is 1700-fold less
FT                   potently inhibited by the alpha-conotoxin RgIA."
FT                   /evidence="ECO:0000269|PubMed:22774872,
FT                   ECO:0000269|PubMed:25740413"
FT   MUTAGEN         101
FT                   /note="R->G: No significant change in potency of inhibition
FT                   of the CHRNA9-CHRNA10 receptor by the alpha-conotoxin
FT                   RgIA."
FT                   /evidence="ECO:0000269|PubMed:22774872"
FT   MUTAGEN         146
FT                   /note="D->L: Complete loss of inhibition of the CHRNA9-
FT                   CHRNA10 receptor by the alpha-conotoxin RgIA."
FT                   /evidence="ECO:0000269|PubMed:25740413"
FT   MUTAGEN         147
FT                   /note="S->A: No significant change in potency of inhibition
FT                   of the CHRNA9-CHRNA10 receptor by the alpha-conotoxin
FT                   RgIA."
FT                   /evidence="ECO:0000269|PubMed:22774872"
FT   MUTAGEN         166
FT                   /note="S->N: No significant change in potency of inhibition
FT                   of the CHRNA9-CHRNA10 receptor by the alpha-conotoxin
FT                   RgIA."
FT                   /evidence="ECO:0000269|PubMed:22774872"
FT   MUTAGEN         176
FT                   /note="W->T: The CHRNA9-CHRNA10 receptor is 8.5-fold less
FT                   potently inhibited by the alpha-conotoxin RgIA."
FT                   /evidence="ECO:0000269|PubMed:18295795"
FT   CONFLICT        425
FT                   /note="T -> A (in Ref. 1; AAA56720)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   479 AA;  54526 MW;  CBB3E15E9DF68837 CRC64;
     MNRPHSCLSF CWMYFAASGI RAVETANGKY AQKLFSDLFE DYSSALRPVE DTDAVLNVTL
     QVTLSQIKDM DERNQILTAY LWIRQTWHDA YLTWDRDQYD RLDSIRIPSD LVWRPDIVLY
     NKADDESSEP VNTNVVLRYD GLITWDSPAI TKSSCVVDVT YFPFDSQQCN LTFGSWTYNG
     NQVDIFNALD SGDLSDFIED VEWEVHGMPA VKNVISYGCC SEPYPDVTFT LLLKRRSSFY
     IVNLLIPCVL ISFLAPLSFY LPAASGEKVS LGVTILLAMT VFQLMVAEIM PASENVPLIG
     KYYIATMALI TASTALTIMV MNIHFCGAEA RPVPHWAKVV ILKYMSRILF VYDVGESCLS
     PRHSQEPEQV TKVYSKLPES NLKTSRNKDL SRKKEVRKLL KNDLGYQGGI PQNTDSYCAR
     YEALTKNIEY IAKCLKDHKA TNSKGSEWKK VAKVIDRFFM WIFFAMVFVM TVLIIARAD
//
